Vincerx Pharma (VINC)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.12%)
Updated Sep 4, 2024 03:58 PM ET
After-Market: $0.78 0.00 (0.12%) 7:34 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Vincerx Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 13 | 53 | 112 | 62 | 0 |
Receivables | 1 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 3 | 0 | 1 | 0 |
Total Current Assets | 15 | 56 | 112 | 63 | 0 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 2 | 0 | 0 |
Total Assets | 18 | 59 | 118 | 63 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 5 | 5 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 6 | 5 | 0 |
Total Current Liabilities | 6 | 9 | 14 | 6 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7 | 12 | 17 | 6 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 170 | 169 | 156 | 68 | 0 |
Retained Earnings | -159 | -121 | -56 | -11 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 11 | 48 | 100 | 58 | 0 |
Total Liabilities & Shareholder's Equity | 18 | 59 | 118 | 63 | 0 |
Total Common Equity | 11 | 48 | 100 | 58 | 0 |
Shares Outstanding | 21.30 | 21.10 | 21.00 | 13.90 | NA |
Book Value Per Share | 0.53 | 2.26 | 4.78 | 4.15 | 0.00 |
Fiscal Year End for Vincerx Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 16 | 5 | 13 | 21 | 27 |
Receivables | 1 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 3 |
Total Current Assets | 18 | 8 | 15 | 23 | 32 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1 | 1 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 1 | 1 | 1 |
Total Assets | 22 | 11 | 18 | 26 | 35 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 2 | 5 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 5 | 0 | 0 | 0 |
Total Current Liabilities | 5 | 11 | 6 | 9 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 12 | 7 | 11 | 11 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 189 | 171 | 170 | 172 | 171 |
Retained Earnings | -173 | -172 | -159 | -157 | -147 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 15 | -1 | 11 | 16 | 24 |
Total Liabilities & Shareholder's Equity | 22 | 11 | 18 | 26 | 35 |
Total Common Equity | 15 | -1 | 11 | 16 | 24 |
Shares Outstanding | 29.60 | 21.40 | 21.30 | 21.30 | 21.20 |
Book Value Per Share | 0.52 | -0.03 | 0.53 | 0.74 | 1.14 |